<unk>  is used as a first- and second-line treatment for symptomatic hairy cell leukemia and for B-cell chronic lymphocytic leukaemia, and is administered by intravenous or subcutaneous infusion. Some investigators have used the parenteral formulation orally to treat patients with hairy cell leukemia. About 37–51% of oral<unk>  is bioavailable orally. It is used, often in combination with other cytotoxic agents, to treat various kinds of histiocytosis, including Erdheim–Chester disease and Langerhans cell histiocytosis. Following EMA approval of<unk>  tablets for the treatment of adult patients with highly active relapsing-remitting multiple sclerosis in 2017, as of July 2020,<unk>  tablets have gained marketing authorisation in over 75 countries. In 2019,<unk>  tablets were approved by the FDA for the treatment of relapsing forms of multiple sclerosis, to include relapsing-remitting disease and active secondary progressive disease, in adult patients who have had an inadequate response to, or are unable to tolerate, an alternate drug indicated for the treatment of multiple sclerosis.<unk>  may cause foetal harm when administered to a pregnant woman and is listed by the FDA as pregnancy category D; safety and efficacy in children has not been established.
Cladribine
Ifosfamide
Fludarabine
Cytarabine
Clofarabine
Vincristine
Nelarabine
Cyclophosphamide